These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 9591584

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma.
    M'Kacher R, Légal JD, Schlumberger M, Aubert B, Beron-Gaillard N, Gaussen A, Parmentier C.
    J Nucl Med; 1997 Mar; 38(3):377-80. PubMed ID: 9074522
    [Abstract] [Full Text] [Related]

  • 4. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay.
    Watanabe N, Yokoyama K, Kinuya S, Shuke N, Shimizu M, Futatsuya R, Michigishi T, Tonami N, Seto H, Goodwin DA.
    J Nucl Med; 1998 Mar; 39(3):436-40. PubMed ID: 9529288
    [Abstract] [Full Text] [Related]

  • 5. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine].
    Katz N, Esik O, Füzy M, Gundy S.
    Orv Hetil; 1998 Jun 21; 139(25):1521-6. PubMed ID: 9676113
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients.
    Serna A, Alcaraz M, Navarro JL, Acevedo C, Vicente V, Canteras M.
    Radiat Prot Dosimetry; 2008 Jun 21; 129(4):372-80. PubMed ID: 17951242
    [Abstract] [Full Text] [Related]

  • 8. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
    De Ruyck K, Lambert B, Bacher K, Gemmel F, De Vos F, Vral A, de Ridder L, Dierckx RA, Thierens H.
    J Nucl Med; 2004 Apr 21; 45(4):612-8. PubMed ID: 15073257
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chromosome aberrations after treatment with radioactive iodine for thyroid cancer.
    Baugnet-Mahieu L, Lemaire M, Léonard ED, Léonard A, Gerber GB.
    Radiat Res; 1994 Dec 21; 140(3):429-31. PubMed ID: 7972697
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer.
    Khvostunov IK, Saenko VA, Krylov V, Rodichev A, Yamashita S.
    Radiat Environ Biophys; 2017 Aug 21; 56(3):213-226. PubMed ID: 28526978
    [Abstract] [Full Text] [Related]

  • 14. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
    Saint-Vil D, Emran MA, Lambert R, Alos N, Turpin S, Huot C.
    J Pediatr Surg; 2007 May 21; 42(5):853-6. PubMed ID: 17502198
    [Abstract] [Full Text] [Related]

  • 15. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
    Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY.
    J Nucl Med; 2006 Oct 21; 47(10):1587-91. PubMed ID: 17015892
    [Abstract] [Full Text] [Related]

  • 16. Individualized dosimetry in the management of metastatic differentiated thyroid cancer.
    Chiesa C, Castellani MR, Vellani C, Orunesu E, Negri A, Azzeroni R, Botta F, Maccauro M, Aliberti G, Seregni E, Lassmann M, Bombardieri E.
    Q J Nucl Med Mol Imaging; 2009 Oct 21; 53(5):546-61. PubMed ID: 19910908
    [Abstract] [Full Text] [Related]

  • 17. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).
    Bianchi L, Baroli A, Lomuscio G, Pedrazzini L, Pepe A, Pozzi L, Chiesa C.
    Q J Nucl Med Mol Imaging; 2012 Dec 21; 56(6):515-21. PubMed ID: 23358404
    [Abstract] [Full Text] [Related]

  • 18. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
    de Carvalho JW, Sapienza M, Ono C, Watanabe T, Guimarães MI, Gutterres R, Marechal MH, Buchpiguel C.
    Nucl Med Commun; 2009 Jul 21; 30(7):533-41. PubMed ID: 19436231
    [Abstract] [Full Text] [Related]

  • 19. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
    Lassmann M, Luster M, Hänscheid H, Reiners C.
    J Nucl Med; 2005 May 21; 46(5):899. PubMed ID: 15872368
    [No Abstract] [Full Text] [Related]

  • 20. 131I ablation treatment in young females after the Chernobyl accident.
    Travis CC, Stabin MG.
    J Nucl Med; 2006 Oct 21; 47(10):1723-7. PubMed ID: 17015910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.